ArticleBMC cancer2025

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.

Jiajin Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.